Microbiome

IP protection to support sustainable commercial development of microbiome-targeting applications. Discovering the influence of microorganisms on health, disease and wellbeing.

Microbiome targeting technology is a rapidly emerging, complex sector which improves human, animal, and crop health and well-being. Having actively advised on a full-range of IP matters involving manipulation and analysis of microbiomes for  almost two decades, HGF has one of the most experienced teams in this area throughout Europe.  

Specialising in therapeutic, diagnostic, nutraceutical, cosmetic and agricultural application, as well as related bioinformatics-powered innovations, the team is well versed in the challenges and opportunities for protecting and commercialising the whole spectrum of microbiome-related inventions, and assists the full range of microbiome-focused companies in developing robust IP strategies, including IP protection, freedom to operate, licensing, European patent opposition and litigation strategies.

Latest updates

When AI Designs the Ingredient: Who Controls the Data, the Model and the Discovery?

AI-enabled discovery has drawn significant attention in pharmaceutical R&D, but its impact is extending into other industries, across ingredients, food, flavour, fragrance and industrial biotechnology. As AI models advance, the …

Read article

Protecting the AI Drug Discovery Ecosystem: Building an IP Stack Around Targets, Molecules and Medicines

Despite the considerable costs and effort in target identification, candidate generation, selection and advancement to clinical trials, 90% of candidates that enter clinical trials during drug discovery fail (Sun D, …

Read article

Agritech Thymes: UK-EU SPS agreement – what does it mean for plant breeders?

Since Brexit, the UK agrifood sector has faced difficulties, largely due to the requirement for additional certifications and controls, such as phytosanitary certificates and border checks. This has had a …

Read article

How Low Can You Go? T 0137/24, Percentage Sequence Identity Claims and Divergent EPO and USPTO Approaches

Key takeaways Increasing percentage sequence identity thresholds may be selected from a disclosed convergent list without adding matter, provided the amendment does not create a new technical combination; Broader percentage …

Read article
Event - 18th November 2026

HGF Venture: Funding the Future

Join fellow life sciences founders, investors and business leaders for an evening of drinks and networking in Cambridge on the 18th November, 5-9pm. Featuring an investor-founder round table and an …

Event details

Designing the Exit: IP Strategy for Venture-Backed Biotech

In venture-built biotech, value is not created at the point of exit, but is designed into the asset from the very beginning. The earliest decisions made around a scientific discovery …

Read article

Five Questions VCs Should Ask About IP Before They Invest

Intellectual property diligence too often starts with the wrong question: how many patents does the company have? For venture investors, that is rarely the most revealing answer. The real issue …

Read article
HGF logo

HGF in Conversation: Andrew Tindall on the IP Landscape of Personalised Medicine

How is the convergence of genomics, AI, diagnostics and gene therapies reshaping healthcare, and what does this mean for intellectual property? Andrew Tindall, Patent Director at HGF, recently joined Parola …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our microbiome specialists.